BroadOak provides flexible growth capital and mergers and acquisitions advice for companies in the life sciences industry that provide tools and services. The investment is part of BroadOak's fifth fund and marks the firm's third investment in the last six months in the rapidly growing market of tools and services for cell and gene therapy development and manufacturing. BroadOak previously invested in Accellix as part of a prior fund.

Promising cell therapies continue to progress to the late stages of clinical development and into commercial products, increasing the need for routine and streamlined quality control (QC) process management. Accellix's products streamline a complex but necessary part of cell analysis, providing more robust outcomes and reducing overall QC costs in cell therapy manufacturing.

Filling a gap so biotech startups can advance to the next level
In the biotechnology industry, there is a need for capital among companies that are already commercial and have products with demonstrated success but...